Ventoxen 100 mg (Generic Venetoclax) – Everest Pharmaceuticals

Ventoxen 100 mg is a generic formulation of Venetoclax — a first-in-class BCL-2 inhibitor — manufactured by Everest Pharmaceuticals Ltd. under WHO-GMP certified conditions in Bangladesh. Each tablet contains 100 mg of venetoclax, the same active molecule found in Venclexta® (AbbVie/Genentech/Roche), and is dispensed under the Named Patient Program for patients with CLL/SLL or AML requiring an affordable, quality-assured alternative.

Venetoclax is not a kinase inhibitor or a chemotherapy drug — it works through a fundamentally different mechanism, restoring the cancer cell’s own programmed death pathway rather than directly poisoning rapidly dividing cells.

Healthy cells have a built-in self-destruct mechanism called apoptosis (programmed cell death) that eliminates damaged or unwanted cells. Many leukaemia and lymphoma cells survive by overproducing a protein called BCL-2, which blocks this self-destruct signal and lets cancer cells live indefinitely.

Venetoclax cannot be started at full dose — doing so risks a life-threatening complication called tumour lysis syndrome (TLS). A mandatory 5-week dose ramp-up protects against this.

• Week 1: Start at 20 mg once daily. Your oncologist will arrange TLS prophylaxis — typically high fluid intake, allopurinol, and close blood test monitoring (potassium, phosphate, calcium, uric acid, creatinine) before and after the first dose.
• Week 2: Dose increases to 50 mg once daily, with repeat TLS monitoring at each increase.
• Week 3: Dose increases to 100 mg once daily.
• Week 4: Dose increases to 200 mg once daily.
• Week 5 onwards: Full target dose of 400 mg once daily is reached (CLL/SLL) — AML dosing in combination with azacitidine may differ. Each step-up carries TLS risk and requires monitoring — never skip ahead in the schedule.

Tumour lysis syndrome is venetoclax’s most clinically significant risk, particularly during the ramp-up period and especially with high tumour burden — this is why the dosing schedule and monitoring protocol must be followed exactly.

Follow your oncologist’s exact ramp-up schedule. Once at target dose, take consistently at the same time each day.

• 1
  Take with a meal at approximately the same time each day — food significantly increases venetoclax absorption.
• 2
  Swallow tablets whole with a glass of water. Do not chew, crush, or break.
• 3
  Avoid grapefruit, Seville oranges, and starfruit — these interfere with venetoclax metabolism via CYP3A4, potentially raising drug levels to dangerous levels and increasing TLS risk.
• 4
  If you miss a dose, take it as soon as possible the same day. Do not double up to make up for a missed dose. If more than a day passes, contact your oncologist before resuming.
• 5
  Storage: at room temperature, in original packaging, away from moisture and light.

• ♥
  Support hydration during ramp-up weeks — high fluid intake is part of TLS prevention. Help ensure the patient drinks adequately, especially the day before and during each dose increase.
• ♥
  Watch for TLS warning signs closely — muscle cramps, confusion, irregular heartbeat, or decreased urination during the ramp-up phase need immediate medical attention.
• ♥
  Track the ramp-up schedule carefully — use a calendar to mark each weekly dose increase and ensure blood tests are completed before each step-up, as instructed.